Oxidopamine Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414671

CAS#: 1199-18-4 (free base)

Description: Oxidopamine Free Base is a neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.


Chemical Structure

img
Oxidopamine Free Base
CAS# 1199-18-4 (free base)

Theoretical Analysis

MedKoo Cat#: 414671
Name: Oxidopamine Free Base
CAS#: 1199-18-4 (free base)
Chemical Formula: C8H11NO3
Exact Mass: 169.0739
Molecular Weight: 169.18
Elemental Analysis: C, 56.80; H, 6.55; N, 8.28; O, 28.37

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1199-18-4 (free base)   636-00-0 (HBr)   28094-15-7 (HCl)  

Synonym: Oxidopamine Free Base; CCRIS4342; CCRIS-4342; CCRIS 4342; 6-Hydroxydopamine

IUPAC/Chemical Name: 5-(2-aminoethyl)benzene-1,2,4-triol

InChi Key: DIVDFFZHCJEHGG-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H11NO3/c9-2-1-5-3-7(11)8(12)4-6(5)10/h3-4,10-12H,1-2,9H2

SMILES Code: NCCc1c(O)cc(O)c(O)c1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 169.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pantic I, Cumic J, Skodric SR, Dugalic S, Brodski C. Oxidopamine and oxidative stress: Recent advances in experimental physiology and pharmacology. Chem Biol Interact. 2021 Feb 25;336:109380. doi: 10.1016/j.cbi.2021.109380. Epub 2021 Jan 13. PMID: 33450287.

2: Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res. 2007 Apr;11(3-4):151-67. doi: 10.1007/BF03033565. PMID: 17449457.

3: Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. Neurologia. 2017 Oct;32(8):533-539. English, Spanish. doi: 10.1016/j.nrl.2015.06.011. Epub 2015 Aug 21. PMID: 26304655.

4: Matsuura K, Kabuto H, Makino H, Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods. 1997 Apr 25;73(1):45-8. doi: 10.1016/s0165-0270(96)02211-x. PMID: 9130677.

5: Pantic I, Dimitrijevic D, Nesic D, Petrovic D. Gray level co-occurrence matrix algorithm as pattern recognition biosensor for oxidopamine-induced changes in lymphocyte chromatin architecture. J Theor Biol. 2016 Oct 7;406:124-8. doi: 10.1016/j.jtbi.2016.07.018. Epub 2016 Jul 16. PMID: 27424557.

6: Bouchatta O, Manouze H, Bouali-Benazzouz R, Kerekes N, Ba-M'hamed S, Fossat P, Landry M, Bennis M. Neonatal 6-OHDA lesion model in mouse induces Attention- Deficit/ Hyperactivity Disorder (ADHD)-like behaviour. Sci Rep. 2018 Oct 18;8(1):15349. doi: 10.1038/s41598-018-33778-0. PMID: 30337626; PMCID: PMC6193955.

7: Varešlija D, Tipton KF, Davey GP, McDonald AG. 6-Hydroxydopamine: a far from simple neurotoxin. J Neural Transm (Vienna). 2020 Feb;127(2):213-230. doi: 10.1007/s00702-019-02133-6. Epub 2020 Jan 1. PMID: 31894418.

8: Hsu SW, Hsu PC, Chang WS, Yu CC, Wang YC, Yang JS, Tsai FJ, Chen KY, Tsai CW, Bau DT. Protective effects of valproic acid on 6-hydroxydopamine-induced neuroinjury. Environ Toxicol. 2020 Aug;35(8):840-848. doi: 10.1002/tox.22920. Epub 2020 Mar 13. PMID: 32167238.

9: Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol. 2005 Mar;16(2):63-77. doi: 10.1097/00008877-200503000-00001. PMID: 15767841.

10: Barilar JO, Knezovic A, Perhoc AB, Homolak J, Riederer P, Salkovic-Petrisic M. Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. J Neural Transm (Vienna). 2020 Feb;127(2):231-250. doi: 10.1007/s00702-020-02152-8. Epub 2020 Feb 6. PMID: 32030485; PMCID: PMC7035309.